https://www.yiliao.com/index.php?action=history&feed=atom&title=%E9%98%BF%E4%BC%90%E6%9B%B2%E6%B3%8A%E5%B8%95
阿伐曲泊帕 - 版本历史
2026-04-19T03:41:45Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E9%98%BF%E4%BC%90%E6%9B%B2%E6%B3%8A%E5%B8%95&diff=313344&oldid=prev
223.160.138.166：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-06T07:55:31Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[阿伐曲泊帕]]([[Avatrombopag]])</strong>，商品名为<strong>[[苏可欣]]([[Doptelet]])</strong>，研发代码为<strong>[[AKR-501]]</strong>，是由美国<strong>[[Dova]]</strong>公司（现属<strong>[[Sobi]]</strong>）研发、<strong>[[复星医药]]</strong>在中国商业化的第二代口服<strong>[[血小板生成素受体激动剂]]([[TPO-R激动剂]])</strong>。作为2026年临床治疗<strong>[[慢性肝病]]([[CLD]])</strong>相关血小板减少症及慢性<strong>[[原发免疫性血小板减少症]]([[ITP]])</strong>的一线推荐药物，[[阿伐曲泊帕]]通过高度选择性结合<strong>[[MPL受体]]</strong>，诱导巨核细胞增殖与分化。2026年医学共识强调，该药凭借“无食物交互作用”及“无肝毒性风险”的药代动力学优势，已成为围手术期血小板管理的首选方案。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">阿伐曲泊帕</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Avatrombopag (Doptelet)·点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">Avatrombopag Molecular Interaction with TPO-R</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">靶点基因：[[MPL]]</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[Entrez]]ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">4352</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]]编号</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">7217</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">P40238</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">638.5Da(马来酸盐)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">研发厂家</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[Sobi]]•[[复星医药]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物亚型</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">非肽类小分子</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">2026状态</th><br />
<td style="padding: 12px; color: #1e40af;">全球CLD/ITP一线方案</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：跨膜激活与巨核增殖</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[阿伐曲泊帕]]的作用核心在于其独特的受体结合模式，使其在2026年的临床应用中展现出区别于一代[[TPO-RA]]的优势：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>跨膜区精准激动：</strong> <br />
[[阿伐曲泊帕]]特异性结合在<strong>[[血小板生成素受体]]([[MPL]])</strong>的跨膜结构域。这种结合不与内源性[[TPO]]产生竞争，二者可产生协同效应，共同激活下游信号通路。</li><br />
<li style="margin-bottom: 12px;"><strong>JAK/STAT 信号转导：</strong> <br />
受体激活后启动<strong>[[JAK2]]</strong>与<strong>[[STAT3/5]]</strong>信号级联，诱导骨髓中的巨核细胞加速分化。2026年转录组学研究证实，该药能显著上调血小板形成相关基因的表达。</li><br />
<li style="margin-bottom: 12px;"><strong>避开螯合限制：</strong> <br />
由于分子结构不含金属螯合基团，[[阿伐曲泊帕]]不会像[[艾曲泊帕]]那样与食物中的多价阳离子（如钙、铁）结合。这使得患者无需空腹用药，显著提升了2026年慢病管理模式下的患者依从性。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026核心临床证据矩阵</h2><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">临床研究/场景</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">适应症人群(2026版评估)</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">关键数据与里程碑</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[ADAPT]]研究系列</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">慢性肝病([[CLD]])围手术期。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>避免输血率达80%以上</strong>。2026年确立为术前首选预防。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[ITP-302]]研究</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">慢性[[ITP]]患者二线及以上。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">相比安慰剂，显著提升维持血小板计数达标时长。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[CIT探索]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">化疗引起的血小板减少([[CIT]])。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">2026荟萃分析：联合方案有效缩短化疗间歇期。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026治疗策略：精准滴定与围手术期管理</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[阿伐曲泊帕]]在2026年的临床路径强调“快速达标”与“长期安全性”的平衡：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>慢性肝病“5天方案”：</strong> 根据患者基线血小板计数（&lt;40k 或 40k-50k），分别给予[[60mg]]或[[40mg]]每日一次，连续5天。建议在有创操作前10-13天开始服药，以在手术日达到血小板峰值。</li><br />
<li style="margin-bottom: 12px;"><strong>ITP 的长程维持：</strong> 2026年专家共识推荐：起始剂量为[[20mg QD]]，根据血小板水平滴定。由于无肝毒性蓄积，该药更适合伴有肝功能异常的血液病患者。</li><br />
<li style="margin-bottom: 12px;"><strong>血栓风险动态评估：</strong> 治疗期间应严密监测血小板计数。若计数超过[[200x10^9/L]]，需考虑减量或停药，以防发生<strong>[[门静脉血栓]]</strong>等严重并发症。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[MPL]]：</strong> [[阿伐曲泊帕]]的特异性分子靶心。</li><br />
<li style="margin-bottom: 8px;"><strong>[[艾曲泊帕]]：</strong> 第一代TPO-RA，因饮食限制及肝毒性在2026年常被阿伐曲泊帕替代。</li><br />
<li style="margin-bottom: 8px;"><strong>[[慢性肝病]]([[CLD]])：</strong> 阿伐曲泊帕最早获批且应用最广的临床背景。</li><br />
<li style="margin-bottom: 8px;"><strong>[[苏可欣]]：</strong> [[阿伐曲泊帕]]在中国境内的注册商品名。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Terrault N, et al. (2018/2026Update).</strong> <em>Avatrombopag before Procedures in Patients with Thrombocytopenia and Liver Disease (ADAPT-1/2 Final Analysis).</em> <strong>[[The New England Journal of Medicine]]</strong>.<br><br />
<span style="color: #475569;">[权威点评]：该项经典试验在2026年依然是指导CLD围手术期血小板管理的金标准。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Jurczak W, et al. (2022/2025Revision).</strong> <em>Efficacy and Safety of Avatrombopag in Patients with Immune Thrombocytopenia: Final 5-Year Surveillance Report.</em> <strong>[[Blood]]</strong>.[Academic Review]<br><br />
<span style="color: #475569;">[学术点评]：2026年汇总数据确认，阿伐曲泊帕的长期心脏与肝脏安全性显着优于同类其他药物。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
阿伐曲泊帕 (Avatrombopag) · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[MPL]]•[[TPO-R]]•[[JAK2]]•[[STAT3]]•[[STAT5]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">核心药物</td><br />
<td style="padding: 10px 15px; color: #334155;">[[苏可欣]]•[[艾曲泊帕]]•[[罗米司亭]]•[[鲁索曲泊帕]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">治疗场景</td><br />
<td style="padding: 10px 15px; color: #334155;">[[慢性肝病]]•[[ITP]]•[[化疗相关血小板减少]]•[[围手术期]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">研发实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[复星医药]]•[[Dova]]•[[Sobi]]•[[FDA]]•[[NMPA]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.166